Nurocor
Digitizing Clinical Development from Start to End

With an increase in the number of therapies, especially given the worldwide pandemic of COVID-19, there is a pressing requirement for the discoveries of new medicines and vaccines. This puts pressure on clinical development organizations to speed up their processes for developing safe and effective drugs. However, ongoing clinical trial processes largely depend on manual methods such as using spreadsheets, word documents, and PDF files that tend to slow down the entire drug development lifecycle. Here, it becomes essential for organizations to focus on clinical standards as well as adhere to regulatory compliance. Alongside following the clinical development standards, the utilization of TransCelerate’s Common Protocol Template (CPT), a harmonized and streamlined approach to the format and content of clinical trial protocols, is essential to support organizations in speeding up the drug development process. As a consortium of most of the largest pharmaceutical companies, TransCelerate has identified manual processes as a major issue and introduced a digital data flow initiative to promote automation of clinical trial processes to reduce cycle times and improve data quality. To support this initiative, Nurocor has designed its solution to automate and enable digital data flow of clinical development processes. The company helps optimize clinical studies by shortening study life cycles while improving accuracy and reducing costs. “We help clients bring value from start to finish by enabling digital data flow as defined by TransCelerate,” says Alex Lazar, president and founder, Nurocor.

The company’s Nurocor Clinical Platform (NCP) automates clinical trials right from the protocol, while following standards mandated by the FDA. This shortens cycle times as it enables clients to perform tasks in parallel rather than serially waiting for one process to finish to start another. NCP-based protocol automation also reduces the number of protocol amendments, which can be very complex to make and can take over 90 days to administer. “We can eliminate protocol amendments caused by manual error or omission to reduce the number from typically five to seven to three to four, saving a significant time to market value,” says Lazar.

By eliminating errors and using the standards from the very start patient burden is reduced through the elimination of retestesting and testing that is not required per the standard.

We help clients bring value from start to finish by enabling digital data flow as defined by TransCelerate

Importantly, NCP enables clients to automate their clinical development processes while maximizing the value of what they already have in place. Especially with the COVID-19 situation, where clinical development organizations are trying to develop medications and vaccinations in the fastest possible way, automation helps them get their drugs to the market. Nurocor also helps clients to fully document their clinical trial procedures while submitting to the FDA for approval with complete traceability from protocol all the way to submission data. In fact, NCP allows clients to easily look at the required information and use it in their processes instead of sifting through numerous documents. Nurocor also has simplified the exchange of information with other ecosystem partners using APIs to help clients exchange data and information across systems in a controlled and consistent manner.

With such exemplary features, Nurocor’s NCP platform has gained significant traction in the pharma industry and has added companies like Pfizer to its client list. Moving into the future, Nurocor sees tremendous value in working closely with various participants of the pharma ecosystem like Oracle and Veeva. At the same time, the company is planning to extend digital data flow to cover end-to-end business processes, which means eliminating manual processes completely and help clients across design, planning, execution, and submission. Nurocor also puts emphasis on providing information to clients, at their fingertips, with an easy to use approach. “Ultimately our aim is to help clients leverage information for better trial outcomes and shorter trial time frames without overburdening the patient,” adds Lazar.